Abstract 45P
Background
Immune related adverse events (IrAEs) are a growing challenge in oncology affecting an increasing number of patients and putting a large strain on patient health and hospital resources. The current availability of biomarkers is highly dependent on the affected organ and the management strategy based on consensus or experiences with non-CPI induced autoimmune disease. In this study, we apply proteome analysis of extracellular vesicles from plasma to assess and discover biomarkers with the potential to aid clinical staging and care of patients suffering from IrAEs.
Methods
Thirty-six patients with grade 3-4 IrAEs (colitis, hepatitis or nephritis) were included in the study. Blood samples were collected at hospital admittance before or early in management (At tox), after initiation of high dose immunosuppressive therapy (At management) and after management (After tox). The collected plasma samples were enriched for extracellular vesicles using a novel workflow and analyzed using liquid-chromatography tandem mass spectrometry (LC-MS/MS). The data analysis was performed in R using the Limma package.
Results
The sample workflow allowed median quantification of 2015 proteins in the plasma samples. In patients responding to prednisolone, we found significant decreases in CRP, SAA1 and SAA2 and a significant increase in MMP9 At management compared to At tox. CRP, SAA1 and SAA2 together with EPS8 and CFP was also significantly lowered After tox. By comparing the IrAE subtypes, definite proteins associated to specific toxicities could be identified including ALDOB, ASL and DXCR in hepatitis, SLC47A2 and PRPF40A in colitis and NCAPH in nephritis.
Conclusions
Biomarkers for monitoring IrAE management are needed to improve the clinical care of patients. Our study identifies several proteins that correlate to specific types of IrAEs and to response to toxicity management, thus, constituting relevant IrAE biomarker candidates.
Clinical trial identification
Regional Ethical Commitee reference number: H-21027448.
Legal entity responsible for the study
Capital Region of Denmark.
Funding
Novo Nordisk Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Presenter: Nicholas Venturini
Session: Poster Display
171P - Immune landscape and CLEVER-1 expression in hepatoblastoma
Presenter: Ville Väyrynen
Session: Poster Display
172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
Presenter: Ju Yang
Session: Poster Display
173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer
Presenter: Job Saris
Session: Poster Display
174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity
Presenter: Yizhi Zhan
Session: Poster Display
175P - MicroRNA-548c: An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer
Presenter: Alyaa Dawoud
Session: Poster Display
176P - Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Presenter: Andrea Joaquin Garcia
Session: Poster Display
177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Presenter: Bhawna Deswal
Session: Poster Display
178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.
Presenter: Charlotte Birchall
Session: Poster Display
179P - Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Presenter: Mattia Rediti
Session: Poster Display